Allogeneic peripheral blood stem cell transplantation for active hemophagocytic lymphohistiocytosis.
Hemophagocytic lymphohistiocytosis (HLH) is a lethal disorder of immune dysregulation. Successful allogeneic BMT is the only therapy that has produced long-term disease-free survival. However, for patients with active HLH the outcome of BMT remains poor when compared with those transplanted in remission. We describe a patient with active, recurrent HLH treated with high-dose chemotherapy and related allogeneic peripheral blood stem cell (PBSC) transplantation. Hematologic recovery was rapid and the post-transplant course was uncomplicated. The patient is alive and well 2 1/2 years after transplant. Allogeneic PBSC transplantation may deserve further evaluation as an alternative source of stem cells for transplantation in patients with active HLH.
Department of Pediatrics, Anderson Cancer Center, Houston, TX 77030, USA.
K W
KW
Chan
C A
CA
Mullen
M
M
Korbling
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D006085:Graft Survival; D018380:Hematopoietic Stem Cell Transplantation; D015616:Histiocytosis, Non-Langerhans-Cell / Q000628:therapy*; D006801:Humans; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous